Taniguchi Eiichi, Matsunami Maho, Kimura Takeshi, Yonezawa Daiki, Ishiki Tsuyoshi, Sekiguchi Fumiko, Nishikawa Hiroyuki, Maeda Yuma, Ishikura Hiroyasu, Kawabata Atsufumi
Division of Pharmacology & Pathophysiology, Kinki University School of Pharmacy, Higashi-Osaka 577-8502, Japan.
Toxicology. 2009 Oct 1;264(1-2):96-103. doi: 10.1016/j.tox.2009.07.018. Epub 2009 Jul 30.
Clinical studies suggest that colonic luminal hydrogen sulfide (H(2)S), produced by sulfate-reducing bacteria or through other pathways, might be involved in the pathogenesis of inflammatory bowel disease (IBD). Nonetheless, this hypothesis has been poorly investigated by basic studies using laboratory animals. We thus focused on two enzymes, cystathionine-gamma-lyase (CSE) that generates H(2)S from l-cysteine, and rhodanese that directly or indirectly detoxifies H(2)S, particularly in relation to the colitis induced by dextran sulfate sodium (DSS) in mice. CSE was a major H(2)S-forming enzyme in colonic and renal homogenates from mice and rats, and the rhodanese activity was also detectable in both tissues. Colitis-related symptoms including decreased body weight gain, diarrhea, hematochezia and shortening of colon length were observed in the mice drinking DSS. Those symptoms were not or only slightly attenuated by repeated administration of a CSE inhibitor. CSE activity and protein levels in the colonic tissue did not notably change in the mice with colitis. In contrast, the activity and protein/mRNA levels of rhodanese in the colon, but not kidney, significantly decreased nearly in parallel with the development of colitis, followed by elevation of rhodanese activity in red blood cells (RBCs). These data show that rhodanese, but not CSE, is associated with DSS-induced colitis in mice, leading to a hypothesis that impaired detoxification of H(2)S due to down-regulation or suppression of colonic rhodanese is involved in IBD. The delayed enhancement of rhodanese activity in RBCs, a possible compensative event, might be available as a disease marker for IBD.
临床研究表明,由硫酸盐还原菌产生或通过其他途径产生的结肠管腔硫化氢(H₂S)可能参与炎症性肠病(IBD)的发病机制。尽管如此,这一假说在使用实验动物的基础研究中却很少被探究。因此,我们聚焦于两种酶,即从L-半胱氨酸生成H₂S的胱硫醚-γ-裂解酶(CSE),以及直接或间接使H₂S解毒的硫氰酸酶,特别是与葡聚糖硫酸钠(DSS)诱导的小鼠结肠炎相关的酶。CSE是小鼠和大鼠结肠及肾脏匀浆中主要的H₂S生成酶,并且在这两种组织中也可检测到硫氰酸酶活性。在饮用DSS的小鼠中观察到了与结肠炎相关的症状,包括体重增加减少、腹泻、便血和结肠长度缩短。重复给予CSE抑制剂并不能或仅轻微减轻这些症状。结肠炎小鼠结肠组织中的CSE活性和蛋白水平没有明显变化。相比之下,结肠而非肾脏中的硫氰酸酶活性以及蛋白/ mRNA水平几乎与结肠炎的发展平行显著降低,随后红细胞(RBC)中的硫氰酸酶活性升高。这些数据表明硫氰酸酶而非CSE与小鼠DSS诱导的结肠炎相关,从而提出一个假说,即由于结肠硫氰酸酶下调或受抑制导致的H₂S解毒受损参与了IBD。红细胞中硫氰酸酶活性的延迟增强这一可能的代偿性事件,可能作为IBD的疾病标志物。